In the last five years, Turkey's chemical industry exports have increased by an average annual rate of 5%. These exports make up 5.7% of Turkey’s total exports . The industry exported 4.9 billion in 2008 and this increased by 7.5% in 2009, reaching 5.2 billion dollars. On the other hand, Turkey's chemical industry imports totalled $20 billion in 2009, falling by 21 percent when compared the previous year. 
A Syracuse-based business incubator funded by the New York State Energy Research and Development Authority (NYSERDA) today released the first comprehensive directory created to connect emerging clean technology companies with resources in Central New York that can help develop, grow, and retain businesses in this growing sector. The Clean Tech Asset Guide was published by the Clean Tech Center, a program of the Greater Syracuse Chamber of Commerce located at the Tech Garden in downtown Syracuse. 
The three major universities in Izmir (Ege University, 9 Eylül University and Izmir Institute of Technology) are acknowledged as the national and international authorities in Biomedical Technologies, subjects including but not limited to Bioengineering, Bio-mechanics, and Materials Sciences. Human resources, physical infrastructure, and research results in this field have more than sufficient capacity to lead the Biomedical Technologies Industry and Production Sector, which is now beginning to develop in Izmir. 
By Burcak Akduman - Kyrgyzstan is the only country in Central Asia, the water resources of which are located in its own territory almost entirely, and this is its hydrological peculiarity and advantages, as well as one of its main assets. The water reserves are estimated at approximately 2,458 km3, 1,745 km3 of which are lake waters and 650 km3 in glaciers. The total surface river flow is 50 km3 and groundwater resources make up 13km3. The Kyrgyz Republic is a country, the greatest part of which is surrounded by mountains, with a population of 5.3 million people, 
Biotechnology is a $89 billion a year industry in the U.S. that has produced some 160 drugs and vaccines. According to Erns & Young report, in 2008 the revenues of the publicly traded global biotechnology industry increased by 12%, from US $80.3 billion in 2007 to US$89.7 billion. According to the same report, in Europe, the revenues of publicly traded companies increased by 26%. This growth rate was boosted by the impact of fluctuations in the exchange rate — when stated in euros, revenues grew by 17%. 
